We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tildrakizumab use for recalcitrant pityriasis rubra pilaris.
- Authors
Holmes, Zachary; Goh, Michelle S.; Foley, Peter; Daniel, Benjamin S.
- Abstract
This article discusses the use of tildrakizumab, an interleukin (IL) inhibitor, for the treatment of recalcitrant pityriasis rubra pilaris (PRP). PRP is a rare skin disorder with no approved biologic treatments in Australia. The article presents three cases of PRP that were successfully treated with tildrakizumab, resulting in significant improvements in symptoms and minimal adverse effects. Tildrakizumab is considered a promising therapeutic option for PRP, and further studies are needed to determine its optimal use.
- Subjects
PITYRIASIS rubra; LATENT tuberculosis; PALMOPLANTAR keratoderma; SALICYLIC acid; CYCLOSPORINE; HEART failure
- Publication
Australasian Journal of Dermatology, 2024, Vol 65, Issue 5, p476
- ISSN
0004-8380
- Publication type
Article
- DOI
10.1111/ajd.14307